Literature DB >> 14600246

Basal signaling activity of mu opioid receptor in mouse brain: role in narcotic dependence.

Danxin Wang1, Kirsten M Raehal, Emil T Lin, John J Lowery, Brigitte L Kieffer, Edward J Bilsky, Wolfgang Sadée.   

Abstract

Narcotic analgesics cause addiction by poorly understood mechanisms, involving mu opoid receptor (MOR). Previous cell culture studies have demonstrated significant basal, spontaneous MOR signaling activity, but its relevance to narcotic addiction remained unclear. In this study, we tested basal MOR-signaling activity in brain tissue from untreated and morphine-pretreated mice, in comparison to antagonist-induced withdrawal in morphine-dependent mice. Using guanosine 5'-O-(3-[(35)S]thio)triphosphate ([(35)S]GTP gamma S) binding and adenylyl cyclase activity assay in brain homogenates, we demonstrated that morphine pretreatment of mice enhanced basal MOR signaling in mouse brain homogenates and, moreover, caused persistent changes in the effects of naloxone and naltrexone, antagonists that elicit severe withdrawal in dependent subjects. Naloxone and naltrexone suppressed basal [(35)S]GTP gamma S binding (acting as "inverse agonists") only after morphine pretreatment, but not in drug-naive animals. Moreover, naloxone and naltrexone stimulated adenylyl cyclase activity in striatum homogenates only after morphine pretreatment, by reversing the inhibitory effects of basal MOR activity. After cessation of morphine treatment, the time course of inverse naloxone effects on basal MOR signaling was similar to the time course of naltrexone-stimulated narcotic withdrawal over several days. The neutral antagonist 6 beta-naltrexol blocked MOR activation without affecting basal signaling (G protein coupling and adenylyl cyclase regulation) and also elicited substantially less severe withdrawal. These results demonstrate long-lasting regulation of basal MOR signaling as a potential factor in narcotic dependence.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14600246     DOI: 10.1124/jpet.103.054049

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  38 in total

1.  Shared mechanisms for opioid tolerance and a transition to chronic pain.

Authors:  Elizabeth K Joseph; David B Reichling; Jon D Levine
Journal:  J Neurosci       Date:  2010-03-31       Impact factor: 6.167

2.  Pharmacological characterization of a novel cannabinoid ligand, MDA19, for treatment of neuropathic pain.

Authors:  Jijun J Xu; Philippe Diaz; Fanny Astruc-Diaz; Suzanne Craig; Elizandro Munoz; Mohamed Naguib
Journal:  Anesth Analg       Date:  2010-06-03       Impact factor: 5.108

3.  Conformation state-sensitive antibodies to G-protein-coupled receptors.

Authors:  Achla Gupta; Fabien M Décaillot; Ivone Gomes; Oleg Tkalych; Andrea S Heimann; Emer S Ferro; Lakshmi A Devi
Journal:  J Biol Chem       Date:  2006-12-04       Impact factor: 5.157

4.  In vivo pharmacological resultant analysis reveals noncompetitive interactions between opioid antagonists in the rat tail-withdrawal assay.

Authors:  E A Walker
Journal:  Br J Pharmacol       Date:  2006-10-30       Impact factor: 8.739

5.  Shadows across mu-Star? Constitutively active mu-opioid receptors revisited.

Authors:  Mark Connor
Journal:  Br J Pharmacol       Date:  2009-04       Impact factor: 8.739

6.  Naltrexone Facilitates Learning and Delays Extinction by Increasing AMPA Receptor Phosphorylation and Membrane Insertion.

Authors:  Cherkaouia Kibaly; Angel Y F Kam; Horace H Loh; Ping-Yee Law
Journal:  Biol Psychiatry       Date:  2015-05-02       Impact factor: 13.382

7.  Response to paper by Kelly et al "The opioid receptor pharmacology of GSK1521498 compared to other ligands with different effects on compulsive reward-related behaviors" published in Psychopharmacology 232, 305-314, 2014.

Authors:  Danxin Wang; Wolfgang Sadee
Journal:  Psychopharmacology (Berl)       Date:  2015-03-06       Impact factor: 4.530

8.  Reply to Wang and Sadée.

Authors:  Graeme Henderson; Edward T Bullmore
Journal:  Psychopharmacology (Berl)       Date:  2015-03-11       Impact factor: 4.530

Review 9.  Regulation of μ-opioid receptors: desensitization, phosphorylation, internalization, and tolerance.

Authors:  John T Williams; Susan L Ingram; Graeme Henderson; Charles Chavkin; Mark von Zastrow; Stefan Schulz; Thomas Koch; Christopher J Evans; Macdonald J Christie
Journal:  Pharmacol Rev       Date:  2013-01-15       Impact factor: 25.468

10.  Comparison of naltrexone, 6alpha-naltrexol, and 6beta-naltrexol in morphine-dependent and in nondependent rhesus monkeys.

Authors:  Jun-Xu Li; Lance R McMahon; Charles P France
Journal:  Psychopharmacology (Berl)       Date:  2007-09-16       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.